Literature DB >> 15814620

Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma.

Karin Jöhrer1, Claudia Zelle-Rieser, Alexander Perathoner, Patrizia Moser, Martina Hager, Reinhold Ramoner, Hubert Gander, Lorenz Höltl, Georg Bartsch, Richard Greil, Martin Thurnher.   

Abstract

There is increasing evidence that chemokines and chemokine receptors are causally involved in tumorigenesis by facilitating tumor proliferation and metastasis. Little is known about the possible function of chemokine receptors in the development and progression of renal cell carcinoma (RCC). We, therefore, analyzed the expression of chemokine receptors in tumor specimens and adjacent healthy kidney tissues [normal kidney cell (NKC)] from 10 RCC patients. We also characterized the permanent RCC cell line A-498. CCR6, CXCR2, and CXCR3 were consistently expressed by both malignant cells and NKCs. A-498 displayed additional expression of CXCR4. Importantly, the expression of CCR3 was almost absent on NKCs but clearly enhanced in a substantial proportion of RCC specimens. The primary CCR3 ligand, eotaxin-1/CCL11, induced intracellular Ca2+ mobilization, receptor internalization, and proliferation in A-498 cells confirming signaling competence of RCC-associated CCR3. In addition, we screened tumor tissue sections of 219 patients and found that 28% (62 of 219) expressed the CCR3 receptor. The presence of CCR3 in tumor samples seemed to correlate with the grade of malignancy. Previous work has established that eotaxin-1 expression is induced by tumor necrosis factor-alpha, a cytokine known to be present in RCC tissue. Our data, therefore, supports a scenario in which eotaxin-1 as part of tumor-associated inflammation promotes progression and dissemination of CCR3-positive RCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15814620     DOI: 10.1158/1078-0432.CCR-04-0405

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  37 in total

Review 1.  CXCR3 in carcinoma progression.

Authors:  Bo Ma; Ahmad Khazali; Alan Wells
Journal:  Histol Histopathol       Date:  2015-02-09       Impact factor: 2.303

Review 2.  Chemokines in tumor angiogenesis and metastasis.

Authors:  Seema Singh; Anguraj Sadanandam; Rakesh K Singh
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

3.  CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer.

Authors:  Manisha Agarwal; Chang He; Javed Siddiqui; John T Wei; Jill A Macoska
Journal:  Prostate       Date:  2012-10-11       Impact factor: 4.104

4.  Chemokine Receptor CCR3 Expression in Malignant Cutaneous Tumors.

Authors:  Yoon-Jin Lee; Dae-Hyun Kim; Sang-Han Lee; Hae-Seon Nam; Mi Ryung Roh; Moon-Kyun Cho
Journal:  Ann Dermatol       Date:  2010-11-05       Impact factor: 1.444

5.  Upregulation of C-X-C chemokine receptor type 1 expression is associated with late-stage gastric adenocarcinoma.

Authors:  Jun Pu Wang; Wan Ming Hu; Kuan Song Wang; Bai Hua Luo; Chang Wu; Zhi Hong Chen; Geng Qiu Luo; Yu Wu Liu; Qin Lai Liu; Jun Yu; Jing He Li; Ji Fang Wen
Journal:  Exp Ther Med       Date:  2012-05-07       Impact factor: 2.447

6.  Role of eotaxin-1 signaling in ovarian cancer.

Authors:  Vera Levina; Brian M Nolen; Adele M Marrangoni; Peng Cheng; Jeffrey R Marks; Miroslaw J Szczepanski; Marta E Szajnik; Elieser Gorelik; Anna E Lokshin
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

Review 7.  Chemokines as therapeutic targets in renal cell carcinoma.

Authors:  Karen L Reckamp; Robert M Strieter; Robert A Figlin
Journal:  Expert Rev Anticancer Ther       Date:  2008-06       Impact factor: 4.512

8.  C-X-C motif receptor 3A enhances proliferation and invasiveness of colorectal cancer cells, and is mediated by C-X-C motif ligand 10.

Authors:  Eriko Nozaki; Takaaki Kobayashi; Hiroaki Ohnishi; Kouki Ohtsuka; Tadahiko Masaki; Takashi Watanabe; Masanori Sugiyama
Journal:  Oncol Lett       Date:  2020-01-21       Impact factor: 2.967

9.  Strong expression of chemokine receptor CXCR4 by renal cell carcinoma correlates with advanced disease.

Authors:  Thomas C Wehler; Claudine Graf; Stefan Biesterfeld; Walburgis Brenner; Jörg Schadt; Ines Gockel; Martin R Berger; Joachim W Thüroff; Peter R Galle; Markus Moehler; Carl C Schimanski
Journal:  J Oncol       Date:  2008-12-30       Impact factor: 4.375

10.  Exacerbation of facial motoneuron loss after facial nerve axotomy in CCR3-deficient mice.

Authors:  Derek A Wainwright; Junping Xin; Nichole A Mesnard; Taylor R Beahrs; Christine M Politis; Virginia M Sanders; Kathryn J Jones
Journal:  ASN Neuro       Date:  2009-12-11       Impact factor: 4.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.